Reviva Pharmaceuticals Holdings Stock Price To Earnings To Growth

RVPHW Stock

USD 0.50 0.08 19.05%

Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Reviva Pharmaceuticals Holdings Company Price To Earnings To Growth Analysis

Reviva Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Reviva Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock
Total Assets		0.95	-0.47	-0.99	-0.72	0.7	-0.47	0.3	0.96	-0.47	1.0	-0.91	0.95	-0.47	0.85
Total Stockholder Equity	0.95		-0.32	-0.93	-0.51	0.51	-0.32	0.05	0.97	-0.32	0.95	-0.89	1.0	-0.32	0.67
Current Deferred Revenue	-0.47	-0.32		0.59	0.86	-0.54	1.0	-0.89	-0.39	1.0	-0.47	0.52	-0.33	1.0	-0.6
Net Debt	-0.99	-0.93	0.59		0.78	-0.73	0.59	-0.39	-0.96	0.59	-0.99	0.94	-0.94	0.59	-0.86
Retained Earnings	-0.72	-0.51	0.86	0.78		-0.87	0.86	-0.85	-0.62	0.86	-0.72	0.74	-0.52	0.86	-0.92
Accounts Payable	0.7	0.51	-0.54	-0.73	-0.87		-0.54	0.58	0.67	-0.54	0.7	-0.77	0.53	-0.54	0.95
Short Term Investments	-0.47	-0.32	1.0	0.59	0.86	-0.54		-0.89	-0.39	1.0	-0.47	0.52	-0.33	1.0	-0.6
Total Liab	0.3	0.05	-0.89	-0.39	-0.85	0.58	-0.89		0.14	-0.89	0.3	-0.28	0.06	-0.89	0.61
Net Invested Capital	0.96	0.97	-0.39	-0.96	-0.62	0.67	-0.39	0.14		-0.39	0.96	-0.97	0.97	-0.39	0.78
Short Long Term Debt	-0.47	-0.32	1.0	0.59	0.86	-0.54	1.0	-0.89	-0.39		-0.47	0.52	-0.33	1.0	-0.6
Total Current Assets	1.0	0.95	-0.47	-0.99	-0.72	0.7	-0.47	0.3	0.96	-0.47		-0.91	0.95	-0.47	0.85
Capital Stock	-0.91	-0.89	0.52	0.94	0.74	-0.77	0.52	-0.28	-0.97	0.52	-0.91		-0.9	0.52	-0.84
Net Working Capital	0.95	1.0	-0.33	-0.94	-0.52	0.53	-0.33	0.06	0.97	-0.33	0.95	-0.9		-0.33	0.68
Short Term Debt	-0.47	-0.32	1.0	0.59	0.86	-0.54	1.0	-0.89	-0.39	1.0	-0.47	0.52	-0.33		-0.6
Common Stock	0.85	0.67	-0.6	-0.86	-0.92	0.95	-0.6	0.61	0.78	-0.6	0.85	-0.84	0.68	-0.6

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Reviva Pharmaceuticals

Reviva Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.0

At this time, Reviva Pharmaceuticals' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Reviva Pharmaceuticals Holdings has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Portfolio Diagnostics Now

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings

All Next

Launch Module

Reviva Fundamentals

	Return On Equity	-17.95
	Return On Asset	-2.34
	Number Of Shares Shorted	17.51 K
	EBITDA	(39.5 T)
	Net Income	(39.26 M)
	Cash And Equivalents	353.26 K
	Cash Per Share	0.02 X
	Total Debt	17.98 M
	Current Ratio	0.03 X
	Book Value Per Share	0.20 X
	Cash Flow From Operations	(28.32 M)
	Number Of Employees	15
	Beta	-0.055
	Market Capitalization	85.81 M
	Total Asset	23.7 M
	Retained Earnings	(134.35 M)
	Working Capital	6.53 M
	Net Asset	23.7 M

About Reviva Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC